Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.

Article  PubMed  CAS  Google Scholar 

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.

Article  PubMed  PubMed Central  Google Scholar 

Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41:113–20.

Article  PubMed  Google Scholar 

Zampella E, Klain M, Pace L, Cuocolo A. PET/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging. 2021;102:515–23.

Article  PubMed  Google Scholar 

Wang H, Dai H, Li Q, Shen G, Shi L, Tian R. Investigating (18)F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol. 2021;11:648658.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yuan L, Wang J, Pan L, Feng H, Chen P, Luo J, et al. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study. Ann Nucl Med. 2023;37:18–25.

Article  PubMed  CAS  Google Scholar 

Bertagna F, Albano D, Bosio G, Piccardo A, Dib B, Giubbini R. 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. It’s value confirmed by a bicentric experience. Curr Radiopharm. 2016;9:228–34.

Article  PubMed  CAS  Google Scholar 

Bang JI, Park S, Kim K, Seo Y, Chong A, Hong CM, et al. the diagnostic value of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin/thyroglobulin antibody levels and negative iodine scintigraphy: a systematic review and meta-analysis. Thyroid : official journal of the American Thyroid Association. 2023;33(10):1224–36.

Piccardo A, Trimboli P, Foppiani L, Treglia G, Ferrarazzo G, Massollo M, et al. PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art. Rev Endocr Metab Disord. 2019;20:47–64.

Article  PubMed  Google Scholar 

Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16.

Article  PubMed  Google Scholar 

Miyauchi A, Kudo T, Kihara M, Higashiyama T, Ito Y, Kobayashi K, et al. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J. 2013;60:415–21.

Article  PubMed  CAS  Google Scholar 

Kelders A, Kennes LN, Krohn T, Behrendt FF, Mottaghy FM, Verburg FA. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions. Nucl Med Commun. 2014;35:176–81.

Article  PubMed  Google Scholar 

Wassermann J, Bernier M-O, Spano J-P, Lepoutre-Lussey C, Buffet C, Simon J-M, et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist. 2016;21:50–8.

Article  PubMed  CAS  Google Scholar 

Cancer IAfRo. WHO Classification of Tumours of Endocrine Organs. In. 2017. https://www.iarc.who.int/news-events/who-classification-of-tumours-of-endocrine-organs/.

Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr Relat Cancer. 2018;25:L7–11.

Article  PubMed  Google Scholar 

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.

Article  PubMed  Google Scholar 

Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221–6.

PubMed  CAS  Google Scholar 

Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16:35.

Article  PubMed  PubMed Central  Google Scholar 

Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20:925–51.

Article  CAS  Google Scholar 

Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019;8:227–45.

Article  PubMed  PubMed Central  Google Scholar 

Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576.

Article  PubMed  Google Scholar 

Lalchandani UR, Sahai V, Hersberger K, Francis IR, Wasnik AP. A radiologist’s guide to response evaluation criteria in solid tumors. Curr Probl Diagn Radiol. 2019;48:576–85.

Article  PubMed  Google Scholar 

Iacobucci D, Posavac SS, Kardes FR, Schneider MJ, Popovich DL. The median split: Robust, refined, and revived. J Consum Psychol. 2015;25:690–704.

Article  Google Scholar 

Monaghan TF, Rahman SN, Agudelo CW, Wein AJ, Lazar JM, Everaert K, et al. Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value. Medicina (Kaunas, Lithuania). 2021;57(5).

Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3–126.

Article  PubMed  Google Scholar 

Zhang X, Higuchi T, Tomonaga H, Lamid-Ochir O, Bhattarai A, Nguyen-Thu H, et al. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine. Nucl Med Commun. 2020;41:350–5.

Article  PubMed  CAS  Google Scholar 

Albano D, Tulchinsky M, Dondi F, Mazzoletti A, Bertagna F, Giubbini RJE. The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. Endocr Relat Cancer. 2021;74:332–9.

CAS  Google Scholar 

Giovanella L, Garo ML, Albano D, Görges R, Ceriani L. The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis. Endocrine Connections. 2022;11(4).

Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab. 2014;99:440–7.

Article  PubMed  CAS  Google Scholar 

Pabst KM, Seifert R, Hirmas N, Broecker-Preuss M, Weber M, Peter Fendler W, et al. Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer. Endocrine Connections. 2023;12(2).

Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 1987;27:115–20.

Article  PubMed  CAS  Google Scholar 

Rössing RM, Jentzen W, Nagarajah J, Bockisch A, Görges RJT. Serum thyroglobulin doubling time in progressive thyroid cancer. Thyroid. 2016;26:1712–8.

Article  PubMed  Google Scholar